| 张 娜,王锦毓,应杰儿.吉西他滨/白蛋白结合型紫杉醇与FOLFIRINOX用于晚期胰腺癌姑息性一线治疗：倾向评分分析解读[J].肿瘤学杂志,2022,28(2):155-162. |
| 吉西他滨/白蛋白结合型紫杉醇与FOLFIRINOX用于晚期胰腺癌姑息性一线治疗：倾向评分分析解读 |
| Study Interpretation： Gemcitabine/nab-Paclitaxel Versus FOLFIRINOX for Palliative First-line Treatment of Advanced Pancreatic Cancer： A Propensity Score Analysis |
| 投稿时间：2022-01-28 |
| DOI：10.11735/j.issn.1671-170X.2022.02.B014 |
|
 |
| 中文关键词: 胰腺导管癌 FOLFIRINOX 吉西他滨/白蛋白结合型紫杉醇 一线治疗 倾向评分 |
| 英文关键词:pancreatic ductal adenocarcinoma cancer FOLFIRINOX gemcitabine/nab-paclitaxel first-line treatment propensity score |
| 基金项目: |
|
| 摘要点击次数: 776 |
| 全文下载次数: 249 |
| 中文摘要: |
| 摘 要：通过比较真实世界接受FOLFIRINOX（亚叶酸+奥沙利铂+伊立替康+氟尿嘧啶）或GN（吉西他滨+白蛋白结合型紫杉醇）方案治疗的晚期胰腺癌患者的临床结果来指导临床实践。该研究为三中心的回顾性队列研究，采用倾向评分逆概率加权法调整研究组之间的混杂因素。FOLFIRINOX组和GN组的主要研究终点(OS)和次要研究终点(PFS、DCR、ORR)在倾向评分矫正前后差异均无统计学意义。FOLFIRINOX组粒缺性发热和腹泻患者发生比例显著高于GN组，而出现中性粒细胞减少、周围神经病变、胆管炎和疲劳症状的比例两组相近。目前尚不能证明FOLFIRINOX方案和GN方案的疗效差异，在临床实践过程中应考虑患者临床特征选择合适的治疗方案。 |
| 英文摘要: |
| Abstract： The study was published in May 2021 in Eur J Cancer written by Riedl JM， Posch F， Horvath L， et al， which compared the clinical outcomes of patients with advanced pancreatic cancer who received FOLFIRINOX(leucovorin+oxaliplatin+ irinotecan+fluorouracil) or GN(gemcitabine/nab?鄄paclitaxel). This was a three?鄄center retrospective cohort study in which propensity score inverse probability weighting was used to adjust for confounding factors in study groups. There was no statistically significant difference in primary end points(OS) and secondary end points(PFS， DCR， ORR) between the FOLFIRINOX and GN groups before and after adjustment. The incidence rates of febrile neutropenia and diarrhea were higher in FOLFIRINOX group， while the rates of any neutropenia， any neuropathy， cholangitis and fatigue symptoms were similar between two groups. There was no evidence of superiority between FOLFIRINOX and GN. The study suggests that clinical characteristics of patients with advanced pancreatic cancer should be considered for choosing appropriate protocols in clinical practice. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |